Navigation Links
FDA Agrees to Amend Dendreon's Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
Date:3/12/2008

se 3 studies (D9901 and D9902A), Dendreon would expect to achieve the pre-specified criterion for significance and would amend the BLA submission with the FDA based on these interim results.

"The amendment of the SPA allows us to accelerate the expected timing of our final results by a year while maintaining comparable power for the study," said Mitchell H. Gold, president and chief executive officer of Dendreon. "Our commitment to helping patients with prostate cancer is unwavering, and we remain focused on providing the necessary data to the FDA as quickly as possible to enable us to bring PROVENGE to the men in need of a new treatment option."

Conference Call Information

Dendreon will host a conference call tomorrow at 8:00 a.m. PT, 11:00 a.m. ET. To access the live call, dial 1-877-548-7901 (domestic) or +1-719-325-4844 (international). The call will also be audio webcast and will be available from the Company's website at http://www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call by dialing 1-888-203-1112 or +1-719-457-0820 for international callers; the conference ID number is 5074038. The replay will be available from 7:30 pm ET on Thursday, March 13 until 11:59 pm ET on Saturday, March 15. In addition the webcast will be archived for on-demand listening for 30 days at http://www.dendreon.com.

About IMPACT Study Design

The IMPACT trial is a randomized, double blind, placebo controlled Phase 3 study, which enrolled just over 500 men with metastatic, androgen independent prostate cancer with a primary endpoint of overall survival.

About Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than o
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
2. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
3. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
4. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
5. Mylan Announces Amendment to Bystolic(TM) (Nebivolol) Agreement
6. Neurobiological Technologies Announces Amendment of License and Cooperation Agreement with Merz Pharmaceuticals and Childrens Hospital
7. Barr Confirms Patent Challenge of Namenda(R) Tablets, 5mg & 10mg
8. ExonHit and bioMerieux Amend Their Strategic Partnership
9. Halozyme Therapeutics Amends Stockholder Rights Plan
10. Beanstalk Capital Ltd. and iCo Therapeutics Inc. amend arrangement agreement
11. Genmab Amends HuMax-CD4 Pivotal Study in CTCL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... 26, 2015  NuGene International, Inc. ("NuGene") (OTCQB: ... skin and hair rejuvenation, has announced that it ... record for investor relations and strategic communications. ... sales and diversification strategies – and we need ... shareholders," stated Ali Kharazmi CEO of NuGene when ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Already well ... gauging line by expanding its Length Gauge offerings with ... gauges. , Specifically, HEIDENHAIN’s pencil probe-style SPECTO ... force specification. Two new 1Vpp, 12mm stroke length ... force applications. One is a variant with a weak ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)... -- Epic Sciences announced today that President and CEO ... Annual Cowen and Company Health Care Conference on Wednesday, March ... Floor. The conference will be held at the Boston ... is developing diagnostic tests of high clinical utility to ... occur during the course of cancer treatments. From a ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... ... Baltimore, MD, USA. This innovative annual event offers a prestigious roster of industry ... safety, scale-up, production, and emerging technologies. , ... Columbia, MD (PRWEB) October 11, 2009 -- METTLER TOLEDO announces ...
... a new "lab-on-a-chip" technique that analyses tiny samples of blood ... cancer much more quickly than ever before. "The concentration ... of metabolized estrogen in breast tissue are known to ... women, and is therefore believed to increase the risk of ...
... the State University of Pennsylvania (USA) and the Universidad ... replicate biological structures, such as butterfly wings, on a ... make optically active structures, such as optical diffusers for ... ability to change colours depending on the angle) or ...
Cached Biology Technology:17th International Process Development Conference to Feature Presentations on Safety, Process Development, Crystallization, PAT, Scale-Up and Production 2New lab-on-a-chip technique developed at U of T 2Nanometric butterfly wings created 2
(Date:2/5/2015)... MOUNTAIN VIEW, Calif. , Feb. 3, 2015 ... screen printer technology, demand from industries such as ... the global market for surface mount technology (SMT) ... manual equipment to automatic control will push the ... glue dispensers will remain steady as glue dispensers ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... to antibiotics acquire said resistance accidentally because they take ... to the stress to which they are subjected., A ... concerning an enigma that the scientific community has still ... the pharmaceutical industry: Why are bacteria becoming increasingly more ...
... and vitamin B12 to treatment with antipsychotic medication improved ... of more than 100 patients. The study focused on ... withdrawal, and a lack of emotional expressiveness. While the ... were more significant in individuals carrying specific variants in ...
... is complicated is an understatement, that it is little understood, ... the brain for three out of the five primary taste ... team of investigators from nine institutions discovered how ATP ... from sweet, bitter, and umami, or savory, taste bud cells. ...
Cached Biology News:New hypothesis: Why bacteria are becoming increasingly more resistant to antibiotics 2Folate and vitamin B12 reduce disabling schizophrenia symptoms in some patients 2Folate and vitamin B12 reduce disabling schizophrenia symptoms in some patients 3Folate and vitamin B12 reduce disabling schizophrenia symptoms in some patients 4How the body's energy molecule transmits 3 types of taste to the brain 2
...
... in two product models - the 5000AT+ and ... that the 6000AT+ includes a membrane desolvation unit ... improved detection limits and reduced oxides. The Ultrasonic ... elements by 10-40 times. Note that with ICP-MS ...
... is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has long ... new radiolabeled ligands selected to keep pace ... range of products and services for receptor ... state-of-the-art radioligands. If you do not find ...
... was developed using a protein engineering approach that ... pocket of wild-type DNase I. These changes markedly ... The result is a versatile enzyme that has ... ability to maintain at least 50% of peak ...
Biology Products: